RAS/P21 transgenic mouse
US6531645B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2000 |
| Grant date | Mar 11, 2003 |
| Priority date | — |
| Expiry date | Nov 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0331
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A transgenic rodent that constitutively expresses a ras protein in at least one tissue, is p21 null in at least one chromosome, and exhibits enhanced and accelerated ras-dependent tumorigenesis, together with methods for using said rodent, or cells derived thereof, for screening compounds or treatments for antitumor activity. In preferred embodiments, the rodent is a transgenic mouse that expresses a human ras oncogene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of a p21WAF1/ClP1transgene, whereby the mouse constitutively expresses a ras oncogene, and has decreased expression of p21. The rodents of the invention are useful in the study of ras-dependent oncogenesis and in the developments of treatments thereto.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.